Trials / Completed
CompletedNCT00192348
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Infants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 6 Weeks – 24 Weeks
- Healthy volunteers
- Accepted
Summary
Trial to compare the safety and tolerability of one and two doses of influenza virus vaccine.
Detailed description
The objective of this study was to compare the safety and tolerability of one and two doses of influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid (CAIV-T) with placebo when administered intranasally to healthy infants aged 6 \< 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAIV-T |
Timeline
- Start date
- 2002-05-01
- Completion
- 2002-12-01
- First posted
- 2005-09-19
- Last updated
- 2021-09-13
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00192348. Inclusion in this directory is not an endorsement.